Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease

25Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

Abstract

Objective: Patients with Parkinson's disease frequently complain of sleep disturbances and loss of muscle atonia during rapid-eye-movement (REM) sleep is not rare. The orexin-A (hypocretin-1) hypothalamic system plays a central role in controlling REM sleep. Loss of orexin neurons results in narcolepsy- cataplexy, a condition characterized by diurnal sleepiness and REM sleep without atonia. Alterations in the orexin-A system have been also documented in Parkinson's disease, but whether these alterations have clinical consequences remains unknown. Methods: Here, we measured orexin-A levels in ventricular cerebrospinal fluid from eight patients with Parkinson's disease (four males and four females) who underwent ventriculography during deep brain-stimulation surgery and performed full-night polysomnography before surgery. Results: Our results showed a positive correlation between orexin-A levels and REM sleep without muscle atonia. Conclusion: Our results suggest that high levels of orexin-A in Parkinson's disease may be associated with loss of REM muscle atonia. © 2013 Bridoux et al, publisher and licensee Dove Medical Press Ltd.

Cite

CITATION STYLE

APA

Bridoux, A., Moutereau, S., Covali-Noroc, A., Margarit, L., Palfi, S., Nguyen, J. P., … Drouot, X. (2013). Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson’s disease. Nature and Science of Sleep, 5, 87–91. https://doi.org/10.2147/NSS.S41245

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free